AstraZeneca's report highlights Tezspire's EU approval for CRSwNP, showcasing significant trial results and market potential. A game-changer for 320M affected globally.
Explore AstraZeneca's latest Form 6-K report detailing promising Saphnelo trial results for SLE, highlighting innovative treatment options and future regulatory steps.
Explore Protagonist Therapeutics' Q4 2024 financial report showcasing $434.4M revenue, $275.2M net income, and a strong 'Buy' recommendation for investors seeking growth in biotech.
Dive into AbbVie Inc.'s 2024 financial performance with $56.33B in revenues, key product insights, and future outlook amid litigation risks. Explore our hold recommendation.
Discover Evaxion Biotech A/S's latest Form 6-K report detailing debt conversion strategies and compliance efforts. Stay informed on AI-Immunology™ advancements and investor relations.